A summary of the CHMP meeting conclusions, including medicines recommended for approval and indication extension and several safety review findings.
List view / Grid view
Filter the results
A study conducted in the US has revealed that the majority of medical marijuana dispensed in the US has THC levels of up to 15 percent.
A Phase Ib trial for the study of the oral formulation for Amphotericin B has met its primary endpoints, demonstrating safety in patients.
Developers have announced that they are ready to manufacture and formulate an innovative novel coronavirus vaccine capsule.
Researchers have created an innovative 3D printing carrier ink to drive the development of personalised biomaterials for cell and drug delivery.
The US FDA has granted Fast Track designation to Jardiance® for the treatment of chronic kidney disease.
The regulatory body has issued guidance based on a complaint that stated a precipitate formed in Aripiprazole 1mg/ml oral solution.
Using AAV-based technology to deliver mAbs in a Phase I trial, researchers report that participants successfully developed antibodies against HIV.
Researchers have identified a tiny protein in scorpion venom that rapidly accumulates in joint cartilage to deliver arthritis drugs in a pre-clinical study.
Tests conducted by an online pharmacy has revealed high levels of NMDA in the diabetes drug metformin, prompting the company to press for a recall.
A new vaccine formulation has been created by researchers, which uses a peelable film during drying to preserve the medicine.
Two companies have announced their partnership to work on the 3D printing of tablets for use in clinical trials.
Europe’s no 1 trade fair for the fine and speciality chemicals industry returns to Cologne with a strong line-up
Chemspec Europe, the International Exhibition for Fine and Speciality Chemicals, returns to Cologne for its 35th edition. From 27 – 28 May 2020, renowned manufacturers, suppliers and distributors of fine and speciality chemicals present their latest products, services and research findings to a dedicated audience of industry experts.
The FDA and EMA have accepted licence applications for ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS).